% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • galaberge galaberge Mar 25, 2013 7:19 AM Flag

    "The consistently strong results of the two Phase 3 studies support the promise of tedizolid as a safe and effective new antibiotic, especia

    "These results confirm Trius' ability to successfully execute a comprehensive clinical program intended to support global approval," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius. "We are committed to responding to the needs of patients and physicians worldwide for new and effective antibiotics. Looking ahead, we intend to file our NDA for tedizolid as well as initiate a Phase 3 study of tedizolid in patients with severe pneumonia during the second half of this year."

    Sentiment: Strong Buy